CPHI Webinar Series

The Outlook for Cell & Gene Therapy Manufacturing

28th June, 2023
4pm CET / 10am EST
What will this webinar address?

The Cell & Gene Therapy space has grown exponentially in the past few years, and the market is predicted to be valued at USD 9 billion by 2027. Continuous advancements in Cell & Gene Therapies have disrupted the industry, transforming how certain diseases, which were previously untreatable by small molecules and biologics, are managed and potentially cured, significantly improving health outcomes for patients worldwide.

While there have been relatively few approvals in the space, investment from private capital is currently at a record high, with projected returns proving alluring for investors. With this in mind, what’s next for Cell & Gene Therapy development and where is it headed?

Join our market outlook webinar, where industry experts will examine the current Cell & Gene Therapy landscape, including innovative approaches to manufacturing, overcoming development and production challenges Cell & Gene Therapies, and forthcoming approvals.

  • Market outlook - high investment, low approval rates – can Cell & Gene Therapies deliver?
  • Beyond oncology: emerging therapies for broader disease areas
  • Addressing industry-wide capacity challenges
  • Allogenic vs autologous manufacturing challenges
  • How analytical tools can pave the way for improved manufacturing efficiencies

Cynthia Pussinen
Executive Advisor & Consultant
Owl Bio Advisors

Cynthia Pussinen has more than 25 years’ experience leading global organizations and high performing teams in the life sciences industry. Her expertise spans the drug development continuum from research through commercialization. She has led the development, licensure, commercialization and subsequent delivery to patients, of more than fifteen new medical therapies for patients globally, including Eraxis® (anidulafungin), ZMAX® (azithromycin) and of LUXTURNA® (voretigene neparvovec-rzyl), the first gene therapy approved in both the United States and the European Union.

Lior Raviv
Chief Technology Officer
Pluristem Therapeutics

Lior Raviv joined Pluristem in 2011 and currently serves as Chief Technology Officer. Prior to that, Mr. Raviv served as Projects manager & Product development Team leader at Pluristem in charge of new technologies and process development. Prior to joining Pluristem and during the years 2010-2011, Mr. Raviv held the position of R&D Analytical Researcher at Teva Pharmaceutical Industries. Mr. Raviv holds an M.Med.Sec in pharmacology from Ben Gurion University and a B.S.c in Biotechnology Engineering from Ben Gurion University.

The Outlook for Cell & Gene Therapy Manufacturing
  • 28th June, 2023
  • 4pm CET / 10am EST
  • 60 minutes
  • Free
CPHI Newsletter

Get the latest from CPHI in your inbox every week.

You understand that your information will be used in accordance with our Privacy Policy, and that you may withdraw your permission to receive any of our communications at any time by clicking on the Unsubscribe link in the Newsletters or opting out on our unsubscribe page page.